Hansa Biopharma: Q2, The European launch is underway - Redeye

Hansa’s European Ideflirix launch is well underway in the Nordics, Benelux, U.K. and Germany. With recent study support, Hansa should be in an excellent position to secure European reimbursement support and a solid uptake in the core patient cohort of very highly sensitized patients. This supports our base case value proposition of SEK 410 (Bear SEK 175 and Bull SEK 600).

https://www.redeye.se/research/817037/hansa-biopharma-q2-the-european-launch-is-underway?utm_source=finwire&utm_medium=RSS